A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Scott, Aaron; H. O’Neil, Bert; L. Gomes, Christina; Baranda, Joaquina; J. Cohen, Steven; Abdulaziz Tejani, Mohamedtaki; T. Maguire, Robert; Wilhelm, François; Maniar, Manoj; Jill Cohen, Deirdre; Wee, Wen; L. Aisner, Dara; K. Cho, Jonathan; Olanrele Olowokure, Olugbenga; L. Coveler, Andrew; R. Menter, Alex; Rubin, Peter; Cusnir, Mike; A. Messersmith, Wells

doi:10.1200/jco.2015.33.3_suppl.342

Public

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Published in Journal of Clinical Oncology • Jan 20, 2015

Authors:

Aaron J. Scott

Bert H. O’Neil

Christina L. Gomes

Abstract

342 Background: Rigosertib (ON 01910.Na), a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase (PI3K) pathways, was assessed in patients with treatment-naïve metastatic pancreatic adenocarcinoma. Methods: Patients with metastatic adenocarcinoma of the pancreas were ran...

Subject

Gemcitabine

Medicine

Pancreatic cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!